<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376049</url>
  </required_header>
  <id_info>
    <org_study_id>EXP-1184</org_study_id>
    <nct_id>NCT02376049</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)</brief_title>
  <official_title>An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults With Mild to Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical
      Agents in Adults with Mild to Moderate Atopic Dermatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, prospective, randomized, vehicle-controlled, investigator-blinded, stable
      lesion design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Sign Score (TSS) change</measure>
    <time_frame>14 days</time_frame>
    <description>TSS change at end of treatment in relation to baseline</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Pimecrolimus cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pimecrolimus 1% cream once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Betamethasone dipropionate cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Betamethasone dipropionate 0.05% cream once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clobetasol propionate cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clobetasol propionate 0.05% cream once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaxal Base cream vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Glaxal Base cream vehicle once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimecrolimus cream</intervention_name>
    <arm_group_label>Pimecrolimus cream</arm_group_label>
    <other_name>Elidel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone dipropionate cream</intervention_name>
    <arm_group_label>Betamethasone dipropionate cream</arm_group_label>
    <other_name>Diprosone</other_name>
    <other_name>Diprolene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol propionate cream</intervention_name>
    <arm_group_label>Clobetasol propionate cream</arm_group_label>
    <other_name>Dermovate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glaxal Base cream vehicle</intervention_name>
    <arm_group_label>Glaxal Base cream vehicle</arm_group_label>
    <other_name>emollient cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with mild to moderate AD

          -  Four comparable TAs

          -  TSS of at least 5 on all TAs

          -  Difference in TSS not greater than 2 between the TAs

          -  Sign score erythema â‰¥ 2 between the TAs

          -  TAs should be at least 2 cm apart

        Exclusion Criteria:

          -  Investigator's opinion

          -  Fitzpatrick skin type &gt;5

          -  Topical (i.e. on the TAs) treatment with prohibited medications

          -  Systemic treatment with prohibited medications

          -  Phototherapy within prohibited timeframe

          -  Use of emollients within prohibited timeframe
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emma Guttmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Innovaderm Research Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beit Harofim</name>
      <address>
        <city>Netanya</city>
        <zip>42701</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Eczema</keyword>
  <keyword>AD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Pimecrolimus</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Clobetasol</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

